Cyclooxygenase-2 selective inhibitor prevents implantation of eutopic endometrium to ectopic sites in rats.
OBJECTIVE
To evaluate Cox-2 inhibition on surgically induced endometriosis in rats.


METHODS
Prospective, randomized study


METHODS
Academic facility.


METHODS
Seventy adult female Sprague-Dawley rats.


METHODS
Uterine fragments were implanted into abdominal peritoneum with suture (site A), and/or into the pelvic cavity without suture (site B). Oral gavage of Cox-2 inhibitor (5 mg/kg/day, twice/day) was started 4 weeks postimplantation (protocol-1), after implantation (protocol-2), or beforehand (protocol-3). Controls received vehicle. Immunohistochemistry evaluated Cox-2 expression after treatment.


METHODS
Presence and size of ectopic implants after treatment.


RESULTS
Protocol-1: After 4 weeks' treatment, size of ectopic implants (site A) was significantly reduced compared with pretreatment size. After 8 weeks' treatment, no ectopic implants were detected in 2 (40%, site A) and 3 (60%, site B) rats. Protocol-2: After 2 weeks' treatment, no ectopic implants were detected in 3 (50%, site A) and 2 (33%, site B) rats. After 4 weeks' treatment, no ectopic implants were detected in 3 (50%, site A) and 3 (50%, site B) rats. Protocol-3: After 2 or 4 weeks' vehicle-only treatment, ectopic implants were in all rats (site B).


CONCLUSIONS
Cox-2 selective inhibition was effective in a rat model of endometriosis, particularly in prevention of ectopic implants.
Matsuzaki
Sachiko
S
Department of Gynecology, Polyclinique de l'Hotel-Dieu, CHU Clermont-Ferrand, Clermont-Ferrand, France. sachikoma@aol.com
Canis
Michel
M
Darcha
Claude
C
Dallel
Radhouane
R
Okamura
Kunihiro
K
Mage
Gerard
G
D000818:Animals; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D004195:Disease Models, Animal; D004334:Drug Administration Schedule; D004715:Endometriosis / Q000201:enzymology / Q000473:pathology / Q000517:prevention & control*; D005260:Female; D007150:Immunohistochemistry; D007527:Isoenzymes / Q000037:antagonists & inhibitors* / Q000378:metabolism; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley
D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D051546:Cyclooxygenase 2; D011451:Prostaglandin-Endoperoxide Synthases